Your browser is no longer supported. Please, upgrade your browser.
Settings
JAZZ Jazz Pharmaceuticals Public Limited Company daily Stock Chart
JAZZ [NASD]
Jazz Pharmaceuticals Public Limited Company
Index- P/E24.81 EPS (ttm)6.42 Insider Own0.90% Shs Outstand58.69M Perf Week4.21%
Market Cap9.35B Forward P/E12.09 EPS next Y13.18 Insider Trans-3.82% Shs Float58.35M Perf Month9.06%
Income396.80M PEG1.38 EPS next Q2.33 Inst Own91.20% Short Float2.39% Perf Quarter33.31%
Sales1.49B P/S6.28 EPS this Y22.70% Inst Trans-0.06% Short Ratio2.50 Perf Half Y35.49%
Book/sh31.33 P/B5.08 EPS next Y18.71% ROA9.50% Target Price179.65 Perf Year4.79%
Cash/sh7.26 P/C21.94 EPS next 5Y18.03% ROE23.00% 52W Range95.80 - 162.25 Perf YTD46.09%
Dividend- P/FCF22.86 EPS past 5Y19.20% ROI11.70% 52W High-1.83% Beta1.24
Dividend %- Quick Ratio2.80 Sales past 5Y40.40% Gross Margin92.90% 52W Low66.26% ATR3.31
Employees1040 Current Ratio2.90 Sales Q/Q16.30% Oper. Margin39.70% RSI (14)67.75 Volatility2.08% 1.91%
OptionableYes Debt/Eq1.08 EPS Q/Q53.60% Profit Margin26.70% Rel Volume0.79 Prev Close162.01
ShortableYes LT Debt/Eq1.06 EarningsMay 30 AMC Payout0.00% Avg Volume557.94K Price159.28
Recom1.80 SMA205.16% SMA5011.18% SMA20025.04% Volume439,054 Change-1.69%
Apr-06-17Downgrade Mizuho Buy → Neutral $162 → $150
Mar-21-17Reiterated Mizuho Buy $152 → $162
Feb-21-17Reiterated Mizuho Buy $127 → $152
Nov-09-16Reiterated Mizuho Buy $185 → $127
Aug-10-16Reiterated Mizuho Buy $195 → $185
Jul-19-16Reiterated Mizuho Buy $193 → $195
Jun-06-16Initiated Goldman Buy $196
May-11-16Upgrade Mizuho Neutral → Buy $137 → $193
May-11-16Reiterated UBS Buy $162 → $168
Apr-25-16Upgrade Sun Trust Rbsn Humphrey Neutral → Buy
Feb-24-16Reiterated Mizuho Neutral $140 → $124
Feb-19-16Initiated Wells Fargo Outperform
Nov-25-15Initiated Bernstein Mkt Perform
Nov-10-15Downgrade Mizuho Buy → Neutral $164 → $140
Oct-14-15Initiated Northland Capital Outperform $200
Oct-09-15Initiated Mizuho Buy
Jun-29-15Reiterated UBS Buy $190 → $210
May-26-15Reiterated Guggenheim Buy $210 → $220
Feb-25-15Reiterated Deutsche Bank Buy $176 → $185
Feb-20-15Initiated BMO Capital Markets Outperform $200
Apr-26-17 04:05PM  Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 2 Study of JZP-110 in Narcolepsy Patients with Excessive Sleepiness PR Newswire
Apr-25-17 04:05PM  Jazz Pharmaceuticals to Report 2017 First Quarter Financial Results on May 9, 2017 PR Newswire
Apr-24-17 04:05PM  Jazz Pharmaceuticals Announces Positive Results from the Phase 2/3 EXPRESS Study of Xyrem in Pediatric Patients with Narcolepsy with Cataplexy PR Newswire
Apr-18-17 02:31PM  Could Lilly Outperform These Bigger Rivals On Strong Diabetes Meds? Investor's Business Daily
Apr-11-17 01:59PM  Jazz Pharmaceuticals, Inc. -- Moody's affirms Jazz Pharma at Ba3; revises outlook to stable from negative Moody's
Apr-08-17 11:32AM  Time for some game theory: A look at Jazz Pharmas latest settlement MarketWatch
Apr-07-17 03:41PM  Should You Drop What You're Doing and Buy Jazz Pharmaceuticals Stock? Motley Fool
Apr-06-17 04:42PM  This Rival Might Swipe 20% Of Jazz's Sleep Business, But Stock Perks Up Investor's Business Daily +9.41%
02:36PM  Market Cheers Jazz Pharmaceuticals Patent Settlement Barrons.com
11:22AM  Jazz Pharma Settles 2010 Xyrem Patent Lawsuit Investopedia
10:32AM  Trevena, Synergy Lead Biotech Movers TheStreet.com
08:39AM  Jazz Pharmaceuticals stock surges 7% on settlement with Hikma over generic drug MarketWatch
Apr-05-17 04:30PM  Jazz Pharmaceuticals Reaches Settlement with Hikma Pharmaceuticals Related to Xyrem Patent Litigation PR Newswire
Apr-04-17 10:28AM  Jazz Pharma Completes NDA Filing for Leukemia Drug to FDA Zacks
Apr-03-17 09:05AM  Jazz Pharmaceuticals Completes Rolling Submission of New Drug Application for Vyxeos (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia PR Newswire
Mar-31-17 08:15AM  Blog Coverage Jazz Pharmaceuticals Inks License Agreement with Nippon Shinyaku Accesswire
03:30AM  Jazz Pharma (JAZZ) Up 7.6% Since Earnings Report: Can It Continue? Zacks
Mar-30-17 02:00AM  Jazz Pharmaceuticals and Nippon Shinyaku Enter Into License Agreements for the Development and Commercialization of Defitelio and Vyxeos in Japan PR Newswire
Mar-24-17 04:41PM  Why You're Smart to Buy Jazz Pharmaceuticals plc Motley Fool
08:15AM  Blog Coverage Stemline Announces Completion of Enrollment for the Stage 3 SL-401 Pivotal Trial Accesswire
Mar-21-17 12:29PM  Actinium Pharmaceuticals (ATNM) Receives New Patents, Boosts Its Portfolio
10:54AM  Jazz Sleep Disorder Drug Positive in Phase III Studies Zacks
Mar-20-17 04:23PM  Jazz Pharma Isn't Dozing; Stock Breaks Out On Sleep Apnea Trial Investor's Business Daily +6.91%
12:42PM  Nektar, AMD, Esperion, and More: Heres Why These Five Stocks Are Surging at Insider Monkey
09:00AM  Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 3 and TONES 4 Studies of JZP-110 in Patients with Obstructive Sleep Apnea PR Newswire
Mar-16-17 11:20AM  Jazz Initiates Phase III Study for Narcolepsy Candidate
Mar-15-17 04:05PM  Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Study Evaluating JZP-258 for the Treatment of Cataplexy and Excessive Daytime Sleepiness in Narcolepsy PR Newswire
Mar-04-17 01:04PM  JAZZ PHARMACEUTICALS PLC Financials
Mar-02-17 09:27AM  Jazz Pharmaceuticals Plc :JAZZ-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017
Mar-01-17 04:22PM  Jazz Pharma (JAZZ) Q4 Earnings Beat, Sales Miss Estimates
04:05PM  Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March PR Newswire
Feb-28-17 09:41PM  Edited Transcript of JAZZ earnings conference call or presentation 28-Feb-17 9:30pm GMT
06:36PM  JAZZ PHARMACEUTICALS PLC Files SEC form 10-K, Annual Report
05:37PM  Jazz beats 4Q profit forecasts
04:30PM  Jazz Pharmaceuticals PLC Earnings Call scheduled for 4:30 pm ET today
04:05PM  Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2016 Financial Results PR Newswire
07:07AM  Q4 2016 Jazz Pharmaceuticals PLC Earnings Release - After Market Close
Feb-23-17 04:20PM  Vetr And Evercore Put Jazz Pharmaceuticals At Buy
08:57AM  Jazz Pharma (JAZZ) Q4 Earnings: Is a Surprise in Store?
Feb-14-17 04:05PM  Jazz Pharmaceuticals to Report 2016 Fourth Quarter and Full Year Financial Results on February 28, 2017 PR Newswire
10:28AM  3 Top Biotech Stocks to Buy on Sale at Motley Fool
Feb-09-17 07:39AM  5 Drug Stocks Poised to Beat Earnings Estimates in Q4
Feb-08-17 04:05PM  Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating JZP-110 for Excessive Sleepiness in Parkinson's Disease PR Newswire
Feb-07-17 04:45PM  Actinium Pharmaceuticals Is Better Than Celator
Feb-04-17 01:31PM  Why Jazz Pharmaceuticals PLC's Shareholders Didn't Sleep on This 12% Gain in January at Motley Fool
Feb-02-17 08:15AM  These 3 Biotech Stocks Are Ridiculously Cheap at Motley Fool
Feb-01-17 08:14AM  Top Healthcare Stocks to Buy in 2017 at Motley Fool
Jan-28-17 08:28AM  3 Most Unbelievably Undervalued Biotech Stocks at Motley Fool
Jan-27-17 11:15AM  Jazz Pharmaceuticals Manufacturing Plant Gets Warning at Investopedia
Jan-23-17 07:13PM  Why Cramer expects nothing good to come of Fitbit at CNBC
Jan-22-17 01:27PM  3 Biotechs Likely to Be Acquired in 2017 at Motley Fool
Jan-19-17 03:34PM  Jazz Pharmaceuticals Plc: Leads amongst peers with strong fundamentals
09:50AM  Can Jazz Pharmaceuticals Be a Top Choice for Value Investors?
Jan-18-17 04:20PM  Jazz Rebuffs Concerns Of Generic Sleep Drug Amid Patent Litigation +11.28%
11:05AM  Wednesdays Top Biopharma Winners
09:26AM  5 Biotech Stocks You'll Want to Watch in the 1st Quarter at Motley Fool
09:15AM  FDA Approves Generic of Jazz Pharma's Sleep Drug at Investopedia
09:13AM  Jazz Pharma, CoLucid Spike Premarket, Plus Other Biotech Movers
08:44AM  Jazz Begins Phase III Study for Label Expansion of Defitelio
06:10AM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Other Events
Jan-17-17 05:28PM  Neurocrine Med Failure, Jazz Pharma Generic Rival OK Sends Both Down
05:16PM  FDA approves generic version of Jazz Pharma's sleep disorder drug Reuters
04:02PM  Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients PR Newswire
Jan-11-17 03:21PM  9 Stocks Trading Below the Peter Lynch Value
Jan-10-17 08:15AM  Blog Coverage Alexion Pharma Applies for US and EU Marketing Approval of Refractory Generalized Myasthenia Gravis Medicine Accesswire
Jan-09-17 05:00PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
11:11AM  Start the New Year off Right with 3 Best Biotech Stocks at Motley Fool
Jan-05-17 10:26AM  Here's Why Jazz Pharmaceuticals PLC Fell Out of Tune and Lost 22% in 2016 at Motley Fool
Jan-04-17 05:49PM  Industrial Companies Showing Good Potential for 2017
Jan-03-17 04:05PM  Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 9 PR Newswire
Jan-02-17 09:03AM  4 Top Stocks on Sale This Winter at Motley Fool
Dec-30-16 05:16PM  Gurus and Insiders Invest in Industrial and Medical Companies
Dec-27-16 10:54AM  Jazz Pharmaceuticals Plc Value Analysis (NASDAQ:JAZZ) : December 27, 2016
Dec-26-16 07:33AM  Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : December 26, 2016
Dec-21-16 10:35AM  What Are Analysts Saying about Horizon Pharma?
Dec-19-16 09:10AM  The Best Biopharma CEOs of 2016 Are...
Dec-18-16 07:06AM  3 Top Healthcare Stocks You've Been Overlooking at Motley Fool
Dec-16-16 01:56PM  ETFs with exposure to Jazz Pharmaceuticals Plc : December 16, 2016
Dec-07-16 01:49PM  Hedge Funds Arent Letting Their Money Stay At Wyndham Worldwide Corporation (WYN) at Insider Monkey
07:29AM  Hedge Funds Are Dumping Jazz Pharmaceuticals plc Ordinary Shares (JAZZ) at Insider Monkey
Dec-05-16 12:16PM  ETFs with exposure to Jazz Pharmaceuticals Plc : December 5, 2016
Nov-29-16 07:51AM  Jazz Completes Patient Enrollment in JZP-110 Narcolepsy Trial
Nov-28-16 04:05PM  Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Study of JZP-110 Evaluating Excessive Sleepiness in Narcolepsy PR Newswire
Nov-25-16 01:14PM  Gurus Invest in Undervalued Biotech Stocks
Nov-14-16 08:15AM  Blog Coverage Gilead Sciences Hepatitis B Drug Vemlidy Approved by European Medicines Agency Accesswire
Nov-10-16 04:05PM  Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences PR Newswire
12:36PM  ETFs with exposure to Jazz Pharmaceuticals Plc : November 10, 2016
Nov-09-16 10:04AM  Jazz Pharmaceuticals Plc :JAZZ-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016 +6.03%
09:07AM  The Market In 5 Minutes: Trump Victory Spooks Stocks
08:48AM  Jazz Pharma (JAZZ) Q3 Earnings Top, Sales Lag Estimates
07:10AM  5 Sectors Poised to Benefit From Donald Trump's Victory at Motley Fool
02:39AM  Edited Transcript of JAZZ earnings conference call or presentation 8-Nov-16 9:30pm GMT
Nov-08-16 05:33PM  Jazz Pharmaceuticals Stock Retreats as Q3 Falls Short
04:30PM  Jazz Pharmaceuticals PLC Earnings Call scheduled for 4:30 pm ET today
Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as phase II clinical trial for ES associated with Parkinson's disease; Vyxeos (CPX-351) for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy, as well as evaluates deuterated oxybate for narcolepsy. In addition, it sells psychiatry and other products. The company is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hooper Suzanne SawochkaEVP & General CounselApr 27Sale160.002,500400,00039,649Apr 28 06:26 PM
WILSON KAREN JSVP, Finance & PAOApr 27Sale160.001,275204,00021,133Apr 27 07:10 PM
MILLER MICHAEL PATRICKSVP, US CommercialApr 17Sale152.5620030,51222,562Apr 19 05:26 PM
COZADD BRUCE CChairman & CEOApr 11Sale152.121,000152,120308,491Apr 13 07:26 PM
WILSON KAREN JSVP, Finance & PAOApr 10Option Exercise51.9311,458595,00329,116Apr 11 08:29 PM
WILSON KAREN JSVP, Finance & PAOApr 10Sale152.2411,4581,744,36622,408Apr 11 08:29 PM
MILLER MICHAEL PATRICKSVP, US CommercialMar 15Sale137.8920027,57822,762Mar 16 05:35 PM
WILSON KAREN JSVP, Finance & PAOMar 08Option Exercise49.363,646179,96722,408Mar 08 05:47 PM
Treacy PaulSVP, Technical OperationsMar 06Sale131.97884116,66617,579Mar 08 05:39 PM
MILLER MICHAEL PATRICKSVP, US CommercialFeb 15Sale134.5520026,91016,486Feb 16 05:13 PM
Cox Russell J.EVP & COOJan 18Sale128.754,000515,00047,095Jan 19 06:29 PM
MILLER MICHAEL PATRICKSVP, US CommercialJan 17Sale115.9320023,18616,686Jan 18 06:32 PM
MILLER MICHAEL PATRICKSVP, US CommercialDec 15Sale103.0920020,61816,886Dec 16 05:09 PM
ENRIGHT PATRICK GDirectorDec 02Sale101.8067768,9191,365Dec 06 04:31 PM
MILLER MICHAEL PATRICKSVP, US CommercialNov 15Sale112.1920022,43816,925Nov 16 05:11 PM
O'Keefe Kenneth WDirectorNov 14Buy112.4550056,2242,000Nov 15 05:12 PM
O'Keefe Kenneth WDirectorNov 11Buy114.311,500171,4651,500Nov 15 05:12 PM
MILLER MICHAEL PATRICKSVP, US CommercialOct 17Sale118.1620023,63217,125Oct 18 05:14 PM
MILLER MICHAEL PATRICKSVP, US CommercialSep 19Sale126.1720025,23417,325Sep 20 05:34 PM
Mulligan SeamusDirectorAug 25Sale128.3227,9683,588,7871,048,008Aug 26 04:24 PM
Treacy PaulSVP, Technical OperationsAug 16Sale137.471,292177,60913,870Aug 18 04:47 PM
MILLER MICHAEL PATRICKSVP, US CommercialAug 15Sale136.4510013,64517,525Aug 16 06:42 PM
Winningham Rick EDirectorAug 15Sale136.4563386,37315,391Aug 17 05:47 PM
Sohn Catherine A.DirectorAug 15Sale136.4563386,3736,116Aug 17 05:41 PM
RIEDEL NORBERT GDirectorAug 15Sale136.4563386,3734,953Aug 17 05:35 PM
McSharry Heather AnnDirectorAug 15Sale136.4568593,4686,076Aug 17 05:31 PM
ENRIGHT PATRICK GDirectorAug 15Sale136.4563386,3732,042Aug 17 05:25 PM
BERNS PAUL LDirectorAug 15Sale136.4563386,3735,234Aug 17 05:20 PM
Smith Karen L.Global Head of R&D and CMOAug 12Buy137.1060883,35614,182Aug 12 04:36 PM
COZADD BRUCE CChairman & CEOAug 09Sale150.001,000150,000299,184Aug 11 04:49 PM
Cox Russell J.EVP & COOAug 09Sale148.664,000594,64051,038Aug 10 04:39 PM
MILLER MICHAEL PATRICKSVP, US CommercialJul 15Sale142.4310014,24317,625Jul 18 07:55 PM
Smith Karen L.Global Head of R&D and CMOJul 13Buy143.6358083,30513,574Jul 13 08:09 PM
MILLER MICHAEL PATRICKSVP, US CommercialJun 15Sale149.6410014,96417,725Jun 16 05:33 PM
Smith Karen L.Global Head of R&D and CMOJun 13Buy149.6155783,33512,994Jun 15 05:17 PM
Mulligan SeamusDirectorMay 24Sale150.2927,9684,203,3391,074,611May 26 05:02 PM
MILLER MICHAEL PATRICKSVP, US CommercialMay 16Sale145.2010014,52017,753May 17 05:56 PM
RIEDEL NORBERT GDirectorMay 16Sale145.2064493,5094,221May 17 05:39 PM
McSharry Heather AnnDirectorMay 16Sale145.20697101,2045,396May 17 05:31 PM